A behavioral intervention to increase vegetable consumption does not reduce the risk for disease progression over 2 years in men with early-stage prostate cancer undergoing active surveillance, phase 3 study data show.
Biochemical relapse-free survival and overall survival rates are comparable in men with localized prostate cancer who start androgen-deprivation therapy before or at the same time as dose-escalated prostate radiotherapy, phase 3 study data show.
Baseline prostate-specific antigen levels in men screened between the ages of 55 and 60 years are significantly associated with long-term risk for clinically significant prostate cancer, shows an analysis of data from the PLCO Cancer Screening Trial.
Men with favorable- and unfavorable-risk prostate cancer who undergo prostatectomy report worse urinary incontinence at 5 years than men treated with other contemporary management options, US research shows.
Treatment with PD-1 inhibitors offers better overall survival, with comparable tolerability, than does treatment with PD-L1 inhibitors for patients with solid tumors such as non-small-cell lung cancer, suggests a systematic review and meta-analysis.
Tumors from obese patients with clear cell renal cell carcinoma have higher angiogenesis scores than those from normal-weight patients, as well as differences in the tumor microenvironment, US researchers report.
A single cycle of adjuvant bleomycin, etoposide, and cisplatin may be enough to reduce rates of malignant recurrence in men with high-risk, stage I, nonseminomatous or combined testicular germ cell tumors, suggests the 111 study.
Pembrolizumab monotherapy shows activity against both RECIST-measurable and bone-predominant treatment-refractory metastatic castration-resistant prostate cancer, results of the KEYNOTE-199 phase 2 trial show.
Adding the potent heat shock protein 90 inhibitor ganetespib to docetaxel does not improve survival among patients with advanced-stage lung adenocarcinoma when used in a second-line setting, results of the GALAXY-2 trial show.